CERo Therapeutics signs up to $8 million Series D convertible preferred financing

CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) said on April 22, 2025 that it signed a securities purchase agreement for a new series of convertible preferred stock, which the company calls its Series D financing. The press release filed as Exhibit 99.1 to the 8-K says gross proceeds could reach up to $8 million. About $5 million is expected at the first closing, through the purchase of securities. Up to $3 million of cash may be funded at one or more later closings, at the investors' election.

The release gives no conversion price, dividend rate or share count for the preferred, and it gives no cash balance or loss figure. It also names no placement agent, underwriter or counsel for the financing. Investors who fund the later closings are not identified.

What the money is for

CERo says it will use the net proceeds to take advantage of two recent FDA IND allowances, in liquid and solid tumors, and to complete site activation at MD Anderson Cancer Center and bring other sites online. The release adds that the proceeds "will also help to address current Nasdaq deficiencies around Shareholders Equity and extend cash on hand to maintain operations and extend runway."

That second use is the more telling one. A company that needs new equity to meet Nasdaq's stockholders' equity standard is raising money to stay listed as well as to fund trials. The release does not give the size of the shortfall, the length of the runway it expects to extend, or the amount of cash the company holds. A reader cannot measure how much of the $8 million goes to the listing problem.

The lead program and its FDA history

The release calls CER-1236 the lead product candidate, and it describes the company as developing engineered T cell therapies for cancer. The company's 10-K, filed April 15, 2025, describes CER-T cells as engineered to engulf cancer cells through phagocytic mechanisms, and it says the approach could span both blood cancers and solid tumors.

The FDA's history with the program is more mixed than the release suggests. The 10-K says the FDA notified the company on November 14, 2024 that the investigational new drug application was cleared, but only after a brief clinical hold. The hold was based on insufficient nonclinical data to judge off-target toxicity. The company says the hold was lifted after additional in vitro experiments. The company has since submitted a second IND for non-small cell lung cancer and ovarian cancer.

The 10-K says the company expects to begin clinical trials in the first half of 2025, with initial targets of relapsed or remitting acute myeloid leukemia patients, patients with measurable residual disease, and patients with TP53 mutations. CEO Chris Ehrlich, quoted in the release, said the company is anticipating the "imminent dosing of our first AML patient at MD Anderson Cancer Center." That is a company statement about the start of dosing, not a result.

What the science does not yet show

The company says CER-1236 cells exhibit superior cross-presentation in preclinical studies. It also says CER-T cells may offer greater therapeutic application than approved CAR-T cell therapy. Both are company claims. The release and the 10-K present no clinical data for the program, and the 10-K itself says trials have not begun.

The 10-K cites the American Cancer Society's estimate of 22,010 new acute myeloid leukemia cases and 11,090 deaths in the United States in 2025. That is the market the company is aiming at. The program has no patient results yet.

Next steps

The release does not give dates beyond the first-half 2025 trial start in the 10-K and the imminent first dosing in the release. It does not say when the Series D closings will occur or what happens if the later $3 million does not fund. Until the first patient is dosed, the company's listing and cash questions rest on a financing whose conversion terms the release does not state.

Report an error

Companies in this story

CEROCERo Therapeutics Holdings, Inc.OTC · United StatesOpen the starter desk